Endo Pharmaceuticals has entered into a collaboration agreement with Orion Corporation for the discovery, development and commercialisation of assets in oncology.
The agreement allows the companies to develop a total of eight “discovery phase” candidates by combining an equal number of programmes.
It also permits the companies to exclusively license others’ development-ready programmes at pre-determined stages and share all development costs.
Endo will retain the marketing rights in North America, while Orion will have marketing rights in Europe.
The companies will pay cross royalties to each other, based on sales from their respective territories, and will mutually decide on the most effective method to maximise product opportunities in rest of world following Phase II studies.
